Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsHyun Jung Kim, MD
Clinical InstructorAbout
Research
Publications
2026
Executive summary of evidence-based clinical practice guideline for Fabry nephropathy
Kim S, Choi S, Park S, Cho E, Han S, Koh E, Chung B, Jeong K, Bae E, Lee E, Kim H, Kang H, Lee B, Kim J, Hong G, Park H, Kwon Y. Executive summary of evidence-based clinical practice guideline for Fabry nephropathy. Kidney Research And Clinical Practice 2026 PMID: 42263771, DOI: 10.23876/j.krcp.26.150.Peer-Reviewed Original ResearchEvidence-based clinical practice guidelinesClinical practice guidelinesPractice guidelinesEvidence-based clinical decisionsAvailability of effective therapeutic optionsFabry nephropathyHealthcare professionalsFabry diseaseExecutive summaryMethodological expertsEffective therapeutic optionKorean Society of NephrologyPatient outcomesEnzyme replacement therapyClinical recommendationsSystematic literature reviewSociety of NephrologyClinical decisionsReplacement therapyTherapeutic optionsGuidelinesEarly diagnosisGenetic disordersChaperone therapyLiterature reviewGenome-wide association study and polygenic risk score analysis for bipolar disorder in the Korean population
Choi M, Kim Y, Lee H, Joo E, Ahn Y, Myung W, Kim S, Lee B, Ha T, Kim S, Chung Y, Kim S, Cho E, Bin Lee D, Huang H, Ha K, Hong K, Won H, Baek J. Genome-wide association study and polygenic risk score analysis for bipolar disorder in the Korean population. Asian Journal Of Psychiatry 2026, 122: 105034. PMID: 42229218, DOI: 10.1016/j.ajp.2026.105034.Peer-Reviewed Original ResearchPredictive performance of polygenic risk scoresGenome-wide association studiesGenome-wide significant lociSingle-nucleotide polymorphismsSignificant lociAssociation studiesPsychiatric genome-wide association studiesPerformance of polygenic risk scoresGenome-wide association study summary statisticsPolygenic risk score analysisIntronic single-nucleotide polymorphismKorean populationPolygenic risk scoresPsychiatric Genomics ConsortiumRisk score analysisSolute carrier familyBipolar disorderGenetic architectureGWAS dataCarrier familyGenomics ConsortiumMitochondrial functionRisk scoreSummary statisticsPopulation dataCo-existence of clinical high-risk for psychosis and bipolar disorder: a multi-dimensional psychopathological analysis
Jeong H, Jang J, Yoon H, Ahn J, Baek J, Kim J, Kang N, Kim J, Jeong J, Kim S. Co-existence of clinical high-risk for psychosis and bipolar disorder: a multi-dimensional psychopathological analysis. BMC Psychiatry 2026 PMID: 42218445, DOI: 10.1186/s12888-026-08220-9.Peer-Reviewed Original ResearchClinical high riskCHR-P criteriaCHR-PBipolar disorderSymptom structureEarly psychopathologyPsychopathological characteristicsMood symptomsPerceptual abnormalitiesPsychiatry clinicPsychosis-Risk SyndromesObsessive-compulsive symptomsSymptom network structureGlobal clinical severityPsychopathological domainsPsychosis-riskDelusional ideationObsessive-CompulsiveManic symptomsSevere moodDiagnostic boundariesMood instabilityObsessive thoughtsSymptom networksSocial withdrawalGlycine-modulating Slc6a20a-ASO restores NMDA receptor function in SHANK2 and SHANK3-mutant mice and cortical organoids
Roh J, Bae M, Oh Y, Yang Y, Lee S, Hwang W, Yang E, Kim H, Jang H, Choi H, Kim H, Kim J, Kim E. Glycine-modulating Slc6a20a-ASO restores NMDA receptor function in SHANK2 and SHANK3-mutant mice and cortical organoids. Nature Communications 2026 PMID: 42215483, DOI: 10.1038/s41467-026-73881-9.Peer-Reviewed Original ResearchNMDA receptor hypofunctionautism spectrum disorderNMDA receptor functionNMDA receptorsASD-related phenotypesprefrontal cortexGlyT1 inhibitionNMDA receptor activationspectrum disorderSHANK3 mutationsco-agonistNMDA receptor encephalitisbrain disordersreceptor functionbrainstem regionsextensive expressioncortical organoidsdisordersShank2mixed outcomescortexhypofunctionNMDAGlyT1phospho-proteomic profilingAvelumab + sacituzumab govitecan (Ave + SG) vs avelumab monotherapy (Ave mono) as first-line (1L) maintenance treatment for advanced urothelial carcinoma (aUC): Updated subgroup analyses of JAVELIN Bladder Medley based on metastatic sites.
Grivas P, Valderrama B, Tsiatas M, Chang P, Kim M, Antonuzzo L, Shin S, Gakis G, Blais N, Kim H, Arija J, Su H, Zagouri F, Maruzzo M, Schneider A, Tyroller K, Hoffman J, Jacob N, Hoffman-Censits J. Avelumab + sacituzumab govitecan (Ave + SG) vs avelumab monotherapy (Ave mono) as first-line (1L) maintenance treatment for advanced urothelial carcinoma (aUC): Updated subgroup analyses of JAVELIN Bladder Medley based on metastatic sites. Journal Of Clinical Oncology 2026, 44: 4568-4568. DOI: 10.1200/jco.2026.44.16_suppl.4568.Peer-Reviewed Original ResearchProgression-free survivalPlatinum-based chemotherapyAdvanced urothelial carcinomaVisceral metastasesMetastatic sitesBone metastasesLiver metastasesOverall survivalPrimary endpointLung metastasesPrimary analysisSubgroup analysisLymph node-only diseaseLymph node-only metastasisSite of visceral metastasisPresence of visceral metastasesTreatment-related adverse eventsAssociated with poor prognosisSite of metastasisMedian Follow-UpPhase 2 trialPhase 3 trialNonvisceral metastasesMetastatic UCData cutoffFirst-in-human phase 1a/1b study of LB-LR1109, an anti-LILRB1 monoclonal antibody, as monotherapy in advanced solid tumors and in combination with atezolizumab in advanced NSCLC.
Cho H, Wang S, Kim J, Yoo T, Park S, Ryu J, Keam B, Kim H, Park H, Lee J, Han J, Perez C, Spira A, Rha S. First-in-human phase 1a/1b study of LB-LR1109, an anti-LILRB1 monoclonal antibody, as monotherapy in advanced solid tumors and in combination with atezolizumab in advanced NSCLC. Journal Of Clinical Oncology 2026, 44: tps2668-tps2668. DOI: 10.1200/jco.2026.44.16_suppl.tps2668.Peer-Reviewed Original ResearchUrothelial carcinomaFirst-in-humanPD-L1HLA-GT cellsOpen-label phase 1 studyAdaptive anti-tumor responsesMultiple immune cell subsetsPhase 1bHuman IgG4 monoclonal antibodyCheckpoint inhibitor resistanceLongitudinal immune profilingMonoclonal antibodiesPD-L1 blockadePD-L1 expressionTumor immune evasionAdvanced solid tumorsAnti-tumor responsesImmune cell subsetsPhase 1 studyT cell functionExcellent safety profileAnti-tumor activityPhase 1aIgG4 monoclonal antibodyNationwide trends in intravenous sedative and analgesic drug use in Korean dental institutions: a big data analysis using the Narcotics Information Management System from 2020 to 2024
Cheon K, Ryoo S, Karm M, Kim H, Han H, Seo K. Nationwide trends in intravenous sedative and analgesic drug use in Korean dental institutions: a big data analysis using the Narcotics Information Management System from 2020 to 2024. Journal Of Dental Anesthesia And Pain Medicine 2026, 26: 247-264. PMID: 42266418, PMCID: PMC13243744, DOI: 10.17245/jdapm.2026.26.085.Peer-Reviewed Original ResearchDental clinicsIV sedationPsychotropic drug useDrug useDental clinic settingAnalgesic drug useDental HospitalDental proceduresDental practiceDental institutionsIntravenous sedationSedative usePsychotropic drugsSedation methodAverage annual growth rateSedationClinical settingClinicKetamineMedical institutionsPatient anxietyMidazolamDrugHospitalSeoul metropolitan areaClinicopathologic characteristics and genomic profiling of HER2-low advanced gastric or gastroesophageal junction cancer
Lee C, Seo D, Park S, Yuh T, Kim Y, Park H, Shim J, Kim H, Kim H, Jung M, Chung H, Rha S. Clinicopathologic characteristics and genomic profiling of HER2-low advanced gastric or gastroesophageal junction cancer. ESMO Open 2026, 11: 106963. PMID: 42127888, PMCID: PMC13196360, DOI: 10.1016/j.esmoop.2026.106963.Peer-Reviewed Original ResearchConceptsHER2-low tumorsImmune checkpoint inhibitorsHER2-lowG/GEJ cancerAdvanced gastricNext-generation sequencingSurvival outcomesFirst-line progression-free survivalHER2-directed antibody-drug conjugateProgrammed death-ligand 1 statusEpstein-Barr virus (EBV)-positiveGenomic profilingHuman epidermal growth factor 2Associated with worse survivalIntermediate survival outcomesProgression-free survivalGastroesophageal junction cancerMolecular featuresYonsei Cancer CenterNext-generation sequencing cohortAntibody-drug conjugatesCheckpoint inhibitorsIHC 0Doublet chemotherapyEBV statusFactors associated with analytical errors in blood chemistry tests
Kim H, Lee S, Cho H, Lee J, Kim S, Lee H, Han J, Chi H, Kim Y. Factors associated with analytical errors in blood chemistry tests. Clinical Chemistry And Laboratory Medicine 2026, 0 PMID: 42105300, DOI: 10.1515/cclm-2026-0153.Peer-Reviewed Original ResearchRoutine blood chemistry parametersAnalytical error ratesBlood chemistry parametersBlood chemistry testsChi-square testRetest dataIon-selective electrodesChemistry parametersAlanine aminotransferaseHigh-concentration analytesChemistry testsError rateAspartate aminotransferaseRetest recordingsAnalyte concentrationComplex assaysTotal testRetesting strategyTest results accuracyTherapeutic Efficacy of PB101 and Chemotherapy Combination in Preclinical Gastric Cancer Models.
Park M, Lee C, Kim K, Hwang S, Sung J, Nam M, Kang M, Park W, Kim J, Kim J, Kim S, Seo J, Jung E, Suh K, Kim Y, Kim J, Lim H, Yang H, Cho E, Lee K. Therapeutic Efficacy of PB101 and Chemotherapy Combination in Preclinical Gastric Cancer Models. Anticancer Research 2026, 46: 2429-2443. PMID: 42049328, DOI: 10.21873/anticanres.18128.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAnimalsAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorCell MovementCell ProliferationCell SurvivalFemaleHumansMiceMice, NudeNeovascularization, PathologicPlacenta Growth FactorStomach NeoplasmsVascular Endothelial Growth Factor AVascular Endothelial Growth Factor BXenograft Model Antitumor AssaysConceptsVascular endothelial growth factor AVEGF receptor 2Gastric cancerTumor microenvironmentVEGF-BTherapeutic efficacyXenograft modelNCI-N87 xenograft modelSingle-agent treatment groupCytotoxic chemotherapeutic agentsPlacental growth factorAnti-angiogenic therapyTube formationEndothelial growth factor AGastric cancer modelCancer-associated deathsAnti-angiogenic effectsGrowth factor AAnti-angiogenic propertiesChemotherapy combinationsHarvested tumorsAnti-angiogenic activityAntitumor efficacyTargeted therapyChemotherapy efficacy